QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
Log in
NASDAQ:KALV

KalVista Pharmaceuticals Stock Forecast, Price & News

$19.26
+0.55 (+2.94 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$18.95
Now: $19.26
$19.50
50-Day Range
$13.30
MA: $17.30
$19.47
52-Week Range
$5.61
Now: $19.26
$20.01
Volume76,657 shs
Average Volume116,610 shs
Market Capitalization$344.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
KalVista Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.97 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075
Employees56

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.69 million
Book Value$4.69 per share

Profitability

Net Income$-29,120,000.00
Net Margins-229.45%

Miscellaneous

Market Cap$344.91 million
Next Earnings Date12/1/2020 (Estimated)
OptionableNot Optionable
$19.26
+0.55 (+2.94 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











KalVista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

How has KalVista Pharmaceuticals' stock been impacted by COVID-19?

KalVista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KALV stock has increased by 117.4% and is now trading at $19.26.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of KalVista Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for KalVista Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than KalVista Pharmaceuticals?

Wall Street analysts have given KalVista Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but KalVista Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is KalVista Pharmaceuticals' next earnings date?

KalVista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, December 1st 2020.
View our earnings forecast for KalVista Pharmaceuticals
.

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) issued its quarterly earnings results on Monday, September, 14th. The specialty pharmaceutical company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.01. KalVista Pharmaceuticals had a negative return on equity of 37.71% and a negative net margin of 229.45%.
View KalVista Pharmaceuticals' earnings history
.

What price target have analysts set for KALV?

3 equities research analysts have issued 12 month target prices for KalVista Pharmaceuticals' stock. Their forecasts range from $25.00 to $39.00. On average, they expect KalVista Pharmaceuticals' stock price to reach $31.33 in the next twelve months. This suggests a possible upside of 62.7% from the stock's current price.
View analysts' price targets for KalVista Pharmaceuticals
.

Are investors shorting KalVista Pharmaceuticals?

KalVista Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 326,900 shares, an increase of 47.0% from the October 31st total of 222,400 shares. Based on an average trading volume of 85,400 shares, the short-interest ratio is presently 3.8 days. Approximately 2.8% of the company's stock are short sold.
View KalVista Pharmaceuticals' Short Interest
.

Who are some of KalVista Pharmaceuticals' key competitors?

What other stocks do shareholders of KalVista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).

Who are KalVista Pharmaceuticals' key executives?

KalVista Pharmaceuticals' management team includes the following people:
  • Mr. Thomas Andrew Crockett, CEO & Director (Age 45, Pay $568k)
  • Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 54, Pay $446.9k)
  • Mr. Christopher M. Yea Ph.D., Chief Devel. Officer (Age 56, Pay $445.27k)
  • Dr. Edward P. Feener, Chief Scientific Officer (Age 60)
  • Leah Monteiro, Director of Corp. Communications & Investor Relations
  • Ms. Rachel Morten, Head of Regulatory Affairs and QA
  • Mr. Andreas Maetzel, Sr. VP of Medical (Age 57)
  • Mr. Michael D. Smith Pharm.D., Sr. VP of Devel. (Age 41)
  • Mr. Stephen Donnelly, Director of Fin. and Company Sec.
  • Mr. John B. McKune, VP of Fin. (Age 44)

What is KalVista Pharmaceuticals' stock symbol?

KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Who are KalVista Pharmaceuticals' major shareholders?

KalVista Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.11%), Logos Global Management LP (1.68%), State Street Corp (1.46%), Boothbay Fund Management LLC (0.74%), Samsara BioCapital LLC (0.47%) and Wells Fargo & Company MN (0.28%). Company insiders that own KalVista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par.
View institutional ownership trends for KalVista Pharmaceuticals
.

Which major investors are selling KalVista Pharmaceuticals stock?

KALV stock was sold by a variety of institutional investors in the last quarter, including Logos Global Management LP, Samsara BioCapital LLC, BlackRock Inc., JPMorgan Chase & Co., Alps Advisors Inc., Charles Schwab Investment Management Inc., and Morgan Stanley. Company insiders that have sold KalVista Pharmaceuticals company stock in the last year include Christopher Yea, and Thomas Andrew Crockett.
View insider buying and selling activity for KalVista Pharmaceuticals
.

Which major investors are buying KalVista Pharmaceuticals stock?

KALV stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, State Street Corp, Boothbay Fund Management LLC, NEXT Financial Group Inc, California Public Employees Retirement System, BNP Paribas Arbitrage SA, Wells Fargo & Company MN, and California State Teachers Retirement System. Company insiders that have bought KalVista Pharmaceuticals stock in the last two years include Albert Cha, and Daniel B Soland.
View insider buying and selling activity for KalVista Pharmaceuticals
.

How do I buy shares of KalVista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is KalVista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $19.26.

How big of a company is KalVista Pharmaceuticals?

KalVista Pharmaceuticals has a market capitalization of $344.91 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-29,120,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. KalVista Pharmaceuticals employs 56 workers across the globe.

What is KalVista Pharmaceuticals' official website?

The official website for KalVista Pharmaceuticals is www.kalvista.com.

How can I contact KalVista Pharmaceuticals?

KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.